\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ \\ pelvic\\ mass\\ \\ \\(especially\\ on\\ bimanual\\ under\\ anesthesia\\)\\	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(34\)\
\-\ lab\\:\\ ua\\ \\-\\ gross\\ hematuria\\,\\ malignant\\ cytology\ \(0\)\
\-\ superficial\\ \\(carcinoma\\ in\\ situ\\)\\:\ \(0\)\
\-\ endoscopic\\ resection\\ with\\ f\\/u\\ q3\\-6\\ mos\ \(0\)\
\-\ recurrence\\:\\ laser\\ therapy\\ or\\ intravesical\\ thiotepa\\,\\ doxorubicin\\,\\ mitomycin\\,\\ or\\ bcg\\.\ \(0\)\
\-\ invasive\\ \\(extension\\ into\\ muscle\\ or\\ perivesical\\ fat\\)\\:\\ \ \(0\)\
\-\ cystectomy\ \(93\)\
\-\ radiation\\ treatment\ \(15\)\
\-\ metastatic\\ \\(grim\\ prognosis\\)\\:\ \(0\)\
\-\ chemotherapy\\:\\ cisplatin\\,\\ methotrexate\\,\\ doxorubicin\\,\\ cyclophosphomide\\,\\ vinblastine\ \(0\)\
\-\ kub\\:\\ \\ punctate\\,\\ coarse\\ linear\\ calcifications\\ encrusted\\ on\\ surface\\ or\\ within\\ tumor\\ located\\ in\\ the\\ bladder\\ region\\ suggests\\ malignancy\\.\ \(0\)\
\-\ carcinoma\\ of\\ the\\ bladder\ \(2\)\
\-\ 73yo\\ african\\ american\\ male\\ with\\ gross\\ hematuria\\,\\ otherwise\\ asymptomatic\ \(0\)\
\-\ demographics\\:\\ men\\ 3x\\'s\\ \\>\\ women\ \(0\)\
\-\ 60\\-70\\ years\\ old\ \(1\)\
\-\ associated\\ with\\ the\\ following\\:\ \(0\)\
\-\ 1\\.\\)\\ exposure\\ to\\ aromatic\\ amines\ \(0\)\
\-\ \\(2\\-naphthylamine\\)\ \(1\)\
\-\ dye\\,\\ chemical\\,\\ rubber\\ industries\ \(1\)\
\-\ 2\\.\\)\\ \\ smokers\ \(0\)\
\-\ 3\\.\\)\\ \\ recurrent\\ nephrolithiasis\ \(0\)\
\-\ 4\\.\\)\\ \\ recurrent\\ uti\\'s\ \(0\)\
\-\ 5\\.\\)\\ \\ travel\\/residence\\ in\\ middle\\ east\ \(0\)\
\-\ chronic\\ schistosomial\\ infections\ \(1\)\
\-\ present\\ with\\ the\\ following\\ symptoms\\:\ \(0\)\
\-\ 1\\.\\)\\ gross\\ hematuria\\ \\(75\\%\\ of\\ patients\\)\\ dysuria\ \(0\)\
\-\ 2\\.\\)\\ frequency\ \(0\)\
\-\ 3\\.\\)\\ urgency\\ \\(25\\%\\ of\\ patients\\)\ \(0\)\
\-\ 4\\.\\)\\ pelvic\\ and\\/or\\ flank\\ pain\ \(0\)\
\-\ 5\\.\\)\\ visceral\\ or\\ osseous\\ pain\\ from\\ metastasis\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gross\\:\\ 0\\.21820943992869027\ \(0\)\
\-\ hematuria\\:\\ 0\\.21747255524695805\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.2042572847605394\ \(0\)\
\-\ or\\:\\ 0\\.17108590593683956\ \(0\)\
\-\ recurrent\\:\\ 0\\.1314444054207585\ \(0\)\
\-\ thiotepa\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ cyclophosphomide\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ 73yo\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ aromatic\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ amines\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ industries\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ schistosomial\\:\\ 0\\.1310805851912474\ \(0\)\
\-\ pelvic\\:\\ 0\\.1281441774268002\ \(0\)\
\-\ bladder\\:\\ 0\\.12721061682369117\ \(0\)\
\-\ intravesical\\:\\ 0\\.12525449703607894\ \(0\)\
\-\ encrusted\\:\\ 0\\.12525449703607894\ \(0\)\
\-\ rubber\\:\\ 0\\.12525449703607894\ \(0\)\
\-\ perivesical\\:\\ 0\\.12112082170557793\ \(0\)\
\-\ dye\\:\\ 0\\.12112082170557793\ \(0\)\
\-\ mitomycin\\:\\ 0\\.11791449402110765\ \(0\)\
\-\ bcg\\:\\ 0\\.11791449402110765\ \(0\)\
\-\ grim\\:\\ 0\\.11791449402110765\ \(0\)\
\-\ east\\:\\ 0\\.11791449402110765\ \(0\)\
\-\ vinblastine\\:\\ 0\\.11529473355040946\ \(0\)\
\-\ 3x\\:\\ 0\\.11307975763289309\ \(0\)\
\-\ cystectomy\\:\\ 0\\.11116105821990846\ \(0\)\
\-\ cisplatin\\:\\ 0\\.11116105821990846\ \(0\)\
\-\ smokers\\:\\ 0\\.10658522796044269\ \(0\)\
\-\ mos\\:\\ 0\\.1021286423802697\ \(0\)\
\-\ demographics\\:\\ 0\\.1021286423802697\ \(0\)\
\-\ urgency\\:\\ 0\\.1021286423802697\ \(0\)\
\-\ bimanual\\:\\ 0\\.10120129473423899\ \(0\)\
\-\ laser\\:\\ 0\\.10033018552160096\ \(0\)\
\-\ following\\:\\ 0\\.09834294722096902\ \(0\)\
\-\ carcinoma\\:\\ 0\\.09805604497670231\ \(0\)\
\-\ cytology\\:\\ 0\\.09662546447477321\ \(0\)\
\-\ visceral\\:\\ 0\\.09537520657907052\ \(0\)\
\-\ anesthesia\\:\\ 0\\.09422508080558473\ \(0\)\
\-\ dysuria\\:\\ 0\\.09368279375440304\ \(0\)\
\-\ kub\\:\\ 0\\.09265600694756904\ \(0\)\
\-\ patients\\:\\ 0\\.09222008727695909\ \(0\)\
\-\ methotrexate\\:\\ 0\\.09216887889460022\ \(0\)\
\-\ situ\\:\\ 0\\.09124153124856951\ \(0\)\
\-\ chemical\\:\\ 0\\.08915542526562772\ \(0\)\
\-\ coarse\\:\\ 0\\.08634279073943174\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.0860269779961472\ \(0\)\
\-\ endoscopic\\:\\ 0\\.08571795745407121\ \(0\)\
\-\ punctate\\:\\ 0\\.08541544309340104\ \(0\)\
\-\ men\\:\\ 0\\.08345937330463345\ \(0\)\
\-\ superficial\\:\\ 0\\.07919566177995825\ \(0\)\
\-\ ua\\:\\ 0\\.07825618335955638\ \(0\)\
\-\ exposure\\:\\ 0\\.0778969421135651\ \(0\)\
\-\ frequency\\:\\ 0\\.0778969421135651\ \(0\)\
\-\ suggests\\:\\ 0\\.0756061406829415\ \(0\)\
\-\ invasive\\:\\ 0\\.07458457039509353\ \(0\)\
\-\ lab\\:\\ 0\\.07403185219906956\ \(0\)\
\-\ african\\:\\ 0\\.07403185219906956\ \(0\)\
\-\ women\\:\\ 0\\.0737632667830641\ \(0\)\
\-\ infections\\:\\ 0\\.07236959447757715\ \(0\)\
\-\ prognosis\\:\\ 0\\.0721301072439685\ \(0\)\
\-\ 75\\:\\ 0\\.07189454620790846\ \(0\)\
\-\ flank\\:\\ 0\\.07189454620790846\ \(0\)\
\-\ american\\:\\ 0\\.06993210581323328\ \(0\)\
\-\ surface\\:\\ 0\\.06838765130029914\ \(0\)\
\-\ under\\:\\ 0\\.06784875434029497\ \(0\)\
\-\ pe\\:\\ 0\\.06776087087740745\ \(0\)\
\-\ recurrence\\:\\ 0\\.06767352166379552\ \(0\)\
\-\ linear\\:\\ 0\\.06602957060981848\ \(0\)\
\-\ osseous\\:\\ 0\\.06542127231062002\ \(0\)\
\-\ the\\:\\ 0\\.06542030243147616\ \(0\)\
\-\ especially\\:\\ 0\\.06483768341614331\ \(0\)\
\-\ located\\:\\ 0\\.06483768341614331\ \(0\)\
\-\ with\\:\\ 0\\.06419943280975887\ \(0\)\
\-\ malignancy\\:\\ 0\\.0613622407915611\ \(0\)\
\-\ in\\:\\ 0\\.06117102533005662\ \(0\)\
\-\ metastasis\\:\\ 0\\.06007461252007543\ \(0\)\
\-\ calcifications\\:\\ 0\\.059820289042103555\ \(0\)\
\-\ pain\\:\\ 0\\.05866050294532164\ \(0\)\
\-\ middle\\:\\ 0\\.058612107022408544\ \(0\)\
\-\ malignant\\:\\ 0\\.05842788781462967\ \(0\)\
\-\ otherwise\\:\\ 0\\.05842788781462967\ \(0\)\
\-\ muscle\\:\\ 0\\.05820088623109485\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.05820088623109485\ \(0\)\
\-\ 25\\:\\ 0\\.0580663869521234\ \(0\)\
\-\ extension\\:\\ 0\\.05802183218343481\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.05580050256190635\ \(0\)\
\-\ radiation\\:\\ 0\\.05431711113660707\ \(0\)\
\-\ resection\\:\\ 0\\.052540914392985506\ \(0\)\
\-\ fat\\:\\ 0\\.05098756200857132\ \(0\)\
\-\ years\\:\\ 0\\.05024371896898054\ \(0\)\
\-\ on\\:\\ 0\\.049509940609426255\ \(0\)\
\-\ region\\:\\ 0\\.049028022488351156\ \(0\)\
\-\ chronic\\:\\ 0\\.04865234353673907\ \(0\)\
\-\ of\\:\\ 0\\.04812082242738535\ \(0\)\
\-\ therapy\\:\\ 0\\.04709446228038256\ \(0\)\
\-\ metastatic\\:\\ 0\\.04495394451159689\ \(0\)\
\-\ symptoms\\:\\ 0\\.04484684661413193\ \(0\)\
\-\ into\\:\\ 0\\.0435714177785475\ \(0\)\
\-\ associated\\:\\ 0\\.04320193433318267\ \(0\)\
\-\ tumor\\:\\ 0\\.042872681597691885\ \(0\)\
\-\ present\\:\\ 0\\.04205913029304725\ \(0\)\
\-\ treatment\\:\\ 0\\.039044489102489775\ \(0\)\
\-\ within\\:\\ 0\\.03775075492130612\ \(0\)\
\-\ male\\:\\ 0\\.03649416771047578\ \(0\)\
\-\ from\\:\\ 0\\.03255319846556931\ \(0\)\
\-\ mass\\:\\ 0\\.031308610639544605\ \(0\)\
\-\ old\\:\\ 0\\.024258473965426956\ \(0\)\
\-\ to\\:\\ 0\\.020491199417781124\ \(0\)\
